An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With or Without Sofosbuvir (SOF) and Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 07 Mar 2018 Results of pooled data from nine clinical trials, were published in the Clinical Pharmacokinetics.
- 12 Jul 2017 Status changed from active, no longer recruiting to completed.
- 27 Jan 2017 Planned number of patients changed from 20 to 30.